We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

D-dimer Assay for Exclusion of Pulmonary Embolism First to Meet Advanced Standards

By LabMedica International staff writers
Posted on 01 Oct 2014
Print article
Diagnostica Stago\'s STA-Liatest D-Di D-dimer assay for exclusion of pulmonary embolism
The STA-Liatest D-Di D-dimer assay for exclusion of pulmonary embolism (Photo courtesy of DIAGNOSTICA STAGO)
For the first time a D-dimer assay for exclusion of pulmonary embolism (PE) meets the US Food and Drug Administration (FDA)’s approval requirements now based on the new and more restrictive standards established by the Clinical Laboratory Standards Institute (CLSI, H59-A).

Diagnostica Stago, Inc. (Parsippany, NJ, USA), the US subsidiary of Diagnostica Stago, S.A.S. (Asnières sur Seine, France), a leader in development and manufacture of hemostasis products for clinical research and routine analysis, received the FDA clearance for the reagent “STA-Liatest D-Di” for the exclusion of PE in patients with low or moderate risk, presenting at an emergency unit. Stago’s rapid, automated, and highly sensitive D-dimer assay is the first to comply with the higher standards.

In order to comply with the new CLSI guidelines, Stago performed a 2-year, international, prospective study, similar to clinical studies performed in the pharmaceutical field—9 sites, 5 countries, more than 1,100 patients, including evaluation of clinical pretest probability, imaging, and 3 months of follow-up—a first in the field of hemostasis diagnostics. As its coordinator, Prof. Gilles Pernod of Grenoble University Hospital (France) pointed out: “As well as providing the results required to validate this test for the exclusion of PE, this study brought to light a significant evolution of clinical practices and shifts in prevalence. In fact, these results will be presented in some interesting upcoming publications.”

This study also confirmed the excellent diagnostic performance of the STA-Liatest D-Di assay, with a very high negative predictive value (NPV) for the exclusion of PE, far exceeding FDA requirements (>99.7% versus 97%), and excellent sensitivity (>97% versus 95%). “STA-Liatest D-Di is the first D-Di assay to report comprehensive study data that focuses on US-specific care patterns in the package insert. Increases in FDA stringency raises the bar for demonstration of clinical utility and patient safety. Stago is proud for STA-Liatest D-Di to lead the way once again and set the standard for D-dimer assays,” said Stephane Zamia, PhD, CEO of Diagnostica Stago, Inc.

The second part of this international clinical study, concerning deep vein thrombosis (DVT), is underway and is due to be completed in the next few months, with the hope that it will provide the clinical science community with as much relevant data as the first.

Related Links:

Diagnostica Stago (US)
Diagnostica Stago 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.